Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Radiotherapy | Editorial

Advances in personalized radiotherapy

Authors: Venkata SK. Manem, Farzad Taghizadeh-Hesary

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Radiotherapy is a mainstay of cancer treatment. The clinical response to radiotherapy is heterogeneous, from a complete response to early progression. Recent studies have explored the importance of patient characteristics in response to radiotherapy. In this editorial, we invite contributions for a BMC Cancer collection of articles titled ‘Advances in personalized radiotherapy’ towards the improvement of treatment response.
Literature
1.
Trapani D, Franzoi MA, Burstein HJ, Carey LA, Delaloge S, Harbeck N, et al. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022;33(7):702–12.CrossRefPubMed
2.
3.
Whelan TJ, Smith S, Nielsen TO, Parpia S, Fyles AW, Bane A, et al. LUMINA: a prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol. 2022;40(17suppl):LBA501–LBA.CrossRef
4.
Gogineni K, Kalinsky K. Individualizing adjuvant therapy in women with hormone Receptor–Positive, human epidermal growth factor receptor 2–Negative node-positive breast Cancer. JCO Oncol Pract. 2022;18(4):247–51.CrossRefPubMed
5.
Heidinger M, Maggi N, Dutilh G, Mueller M, Eller RS, Loesch JM, et al. Use of sentinel lymph node biopsy in elderly patients with breast cancer – 10-year experience from a Swiss university hospital. World J Surg Oncol. 2023;21(1):176.CrossRefPubMedPubMedCentral
6.
Overgaard J, Aznar MC, Bacchus C, Coppes RP, Deutsch E, Georg D, et al. Personalised radiation therapy taking both the tumour and patient into consideration. Radiother Oncol. 2022;166:A1–5.CrossRefPubMed
7.
Osapoetra LO, Dasgupta A, DiCenzo D, Fatima K, Quiaoit K, Saifuddin M, et al. Assessment of clinical radiosensitivity in patients with head-neck squamous cell carcinoma from pre-treatment quantitative ultrasound radiomics. Sci Rep. 2021;11(1):6117.CrossRefPubMedPubMedCentral
8.
Manem VS, Dhawan A. RadiationGeneSigDB: a database of oxic and hypoxic radiation response gene signatures and their utility in pre-clinical research. Br J Radiol. 2019;92(1103):20190198.CrossRefPubMedPubMedCentral
9.
10.
Manem VSK, Dhawan A. Modelling recurrence and second cancer risks induced by proton therapy. Math Med Biol. 2018;35(3):347–61.CrossRefPubMed
11.
Wen S, Ovais M, Li X, Ren J, Liu T, Wang Z, et al. Tailoring bismuth-based nanoparticles for enhanced radiosensitivity in cancer therapy. Nanoscale. 2022;14(23):8245–54.CrossRefPubMed
12.
13.
Taghizadeh-Hesary F, Houshyari M, Farhadi M. Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity. J Cancer Res Clin Oncol. 2023.
14.
Avril D, Foy JP, Bouaoud J, Grégoire V, Saintigny P. Biomarkers of radioresistance in head and neck squamous cell carcinomas. Int J Radiat Biol. 2023;99(4):583–93.CrossRefPubMed
15.
Li Z, Zhang Y, Hong W, Wang B, Chen Y, Yang P, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. Gut Microbes. 2022;14(1):2119055.CrossRefPubMedPubMedCentral
Metadata
Title
Advances in personalized radiotherapy
Authors
Venkata SK. Manem
Farzad Taghizadeh-Hesary
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Radiotherapy
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12317-3

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis

Research

The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer

Research

Identification of key genes in chronic intermittent hypoxia-induced lung cancer progression based on transcriptome sequencing

Research

Identification of FOXP1 as a favorable prognostic biomarker and tumor suppressor in intrahepatic cholangiocarcinoma

Research

CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro

Research

The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits